Company intelligence / Profile preview

Pending AI

Cambridge, Massachusetts, United Statespending.ai ↗

Ownership: Private
Development stage: Preclinical

Overview

Pending AI has developed an advanced artificial intelligence and quantum mechanics-enabled drug discovery platform that accelerates the design of novel small molecules. The company focuses on de novo drug design, structure-based drug design, high-throughput chemistry, and synthesis planning. There are no clinical results as the company provides enabling technology rather than developing its own therapeutic pipeline.

Modalities: Small molecule
Industry: Drug Discovery Services

Beyond the preview

Go deeper on Pending AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pending AI.

Explore the full profile